Clinical development of MVA-based therapeutic cancer vaccines
- PMID: 18767940
- DOI: 10.1586/14760584.7.7.889
Clinical development of MVA-based therapeutic cancer vaccines
Abstract
Tumor-associated antigens (TAAs) have been formulated into vaccines that, combined with adjuvants, cytokines or other strategies to boost the immune response, are now in clinical development. Both humoral and cellular immune responses to TAAs have been generated using these vaccines. This approach relies on the patient's own immune system generating an effective anti-tumor immune response. The advantage of this over therapy with monoclonal antibodies for the treatment of cancer is that multiple antigenic epitopes can be involved and the immune system is able to adapt to the most effective antigenic specificity for tumor growth control and rejection. In this article, we describe the clinical use of vaccinia virus, in particular modified vaccinia virus Ankara (MVA), to express TAAs in vivo and to stimulate an effective immune response to the cancer antigens.
Similar articles
-
Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.Cancer Res. 2003 Nov 15;63(22):7942-9. Cancer Res. 2003. PMID: 14633725
-
5T4-modified vaccinia Ankara: progress in tumor-associated antigen-based immunotherapy.Expert Opin Biol Ther. 2010 Feb;10(2):281-7. doi: 10.1517/14712590903586213. Expert Opin Biol Ther. 2010. PMID: 20088718 Review.
-
The next generation of vaccines for the treatment of cancer.Curr Opin Mol Ther. 1999 Feb;1(1):57-63. Curr Opin Mol Ther. 1999. PMID: 11249685 Review. No abstract available.
-
[Cancer vaccines].Tidsskr Nor Laegeforen. 2006 Nov 16;126(22):2969-73. Tidsskr Nor Laegeforen. 2006. PMID: 17117197 Review. Norwegian.
-
Tumor vaccine: current trends in antigen specific immunotherapy.Indian J Exp Biol. 2005 May;43(5):389-406. Indian J Exp Biol. 2005. PMID: 15900903 Review.
Cited by
-
Strategies for cancer vaccine development.J Biomed Biotechnol. 2010;2010:596432. doi: 10.1155/2010/596432. Epub 2010 Jul 11. J Biomed Biotechnol. 2010. PMID: 20706612 Free PMC article. Review.
-
Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.Expert Rev Vaccines. 2011 Aug;10(8):1221-40. doi: 10.1586/erv.11.79. Expert Rev Vaccines. 2011. PMID: 21854314 Free PMC article. Review.
-
Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen.J Immunother Cancer. 2017 Jan 17;5:4. doi: 10.1186/s40425-016-0204-3. eCollection 2017. J Immunother Cancer. 2017. PMID: 28116088 Free PMC article.
-
Immunological characterization of a modified vaccinia virus Ankara vector expressing the human papillomavirus 16 E1 protein.Clin Vaccine Immunol. 2014 Feb;21(2):147-55. doi: 10.1128/CVI.00678-13. Epub 2013 Dec 4. Clin Vaccine Immunol. 2014. PMID: 24307238 Free PMC article.
-
Vaccine Delivery Methods into the Future.Vaccines (Basel). 2016 Mar 28;4(2):9. doi: 10.3390/vaccines4020009. Vaccines (Basel). 2016. PMID: 27043641 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
